TY - JOUR
T1 - Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder
T2 - Update on recommendations from the British Association for Psychopharmacology
AU - Bolea-Alamañac, Blanca
AU - Nutt, David J.
AU - Adamou, Marios
AU - Asherson, Phillip
AU - Bazire, Stephen
AU - Coghill, David
AU - Heal, David
AU - Müller, Ulrich
AU - Nash, John
AU - Santosh, Paramala
AU - Sayal, Kapil
AU - Sonuga-Barke, Edmund
AU - Young, Susan J.
N1 - Funding Information:
Ulrich Muller has been invited to advisory boards and received educational funding from Janssen Cilag and Eli-Lilly, UK; he has received travel expenses and honoraria from the British Association for Psychopharmacology (BAP), Janssen Cilag, Eli-Lilly, Shire, UCB Pharma and the UK Adult ADHD Network (UKAAN) for talks at scientific and educational meetings.
Funding Information:
Edmund Sonuga- Barke has received speaker, consultancy fees, travel funds and research support from Shire pharmaceuticals, he has also been a member of this company’s advisory board. He has received speaker fees from Janssen Cilag. He has received grants from MRC, ESRC, Wellcome Trust, Solent NHS Trust, European Union, Child Health Research Foundation New Zealand, NIHR, Nuffield Foundation, Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO).
Funding Information:
David Coghill has received research grants from Vifor Pharma and Shire, consultancy fees from Shire and Lundbeck, and speaker fees from Flynn, Janssen-Cilag, Lilly, Medice, Novartis, Shire and Vifor Pharma.
PY - 2014/3
Y1 - 2014/3
N2 - Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment.
AB - Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment.
KW - ADD
KW - ADHD
KW - attention deficit and hyperactivity disorder
KW - BAP
KW - hyperkinetic disorder
UR - http://www.scopus.com/inward/record.url?scp=84895534183&partnerID=8YFLogxK
U2 - 10.1177/0269881113519509
DO - 10.1177/0269881113519509
M3 - Review article
C2 - 24526134
AN - SCOPUS:84895534183
SN - 0269-8811
VL - 28
SP - 179
EP - 203
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 3
ER -
